Stifel lowered the firm’s price target on BioMarin to $108 from $118 and keeps a Buy rating on the shares after reporting “strong” Q2 results. While Roctavian remains a show-me story, it was an “outstanding” quarter for Voxzogo, the analyst tells investors. Voxzogo’s growth, however, may be capacity constrained over the next few quarters and recent key-opinion leader checks remain cautious on the early adoption of Roctavian, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- BioMarin raises FY23 non-GAAP EPS view to $1.85-$2.10 from $1.80-$2.05
- BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
- BioMarin reports Q2 non-GAAP EPS 54c, consensus 23c
- BioMarin options imply 2.3% move in share price post-earnings
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?